Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
The $1.6-billion infusion into its subsidiary is Fujifilm’s latest move to establish a more robust presence in the cell culture manufacturing space.
After the spring reductions in the workforce that left thousands of biotech employees searching for jobs, larger companies are, for the most part, moving forward.
Cellectis shared how its novel immune-evasive universal CAR T cells may potentially deploy large amounts of T-cell product candidates to target multiple malignancies.
Blueprint Medicines announced strategic financing collaborations with Sixth Street and Royalty Pharma for up to $1.25 billion to expand Blueprint’s pipeline and pursue business development opportunities.
Capping off the first half of the year is a flurry of clinical trial wins. BioSpace takes a look at some of the most exciting ones:
AstraZeneca had a very busy week of international news, with progress being shown in China, positive recommendations for two drugs in Europe and a positive clinical trial update.
The biotech industry has been looking for multiple sources of financing, and there has been speculation that big pharma might come to the rescue. But a recent report says that’s unlikely.
There’s quite a bit of movement on the Omicron-specific booster shot and updated supply deals, despite world leaders shifting their attention away from the COVID-19 pandemic.
From search engines to social media, algorithms are quickly becoming a part of everyday life, and companies like Bayer, MIT and others are using them to their advantage.
COVID-19 is much more than a respiratory illness, and many of its longer-term effects and secondary issues are often puzzling. For that and more research news, continue reading.
Many of Innate Pharma’s cancer-fighting products are making clinical progress. BioSpace spoke with the company’s head of product portfolio strategy and business development, Yannis Morel, Ph.D.
The FDA’s decision came after researchers found cases of drug-induced liver injury in some patients. Tolebrutinib is being evaluated for relapsing types of MS, MG, nrSPMS, and PPMS.
PRESS RELEASES
Shareholders Must Recast Their Votes to be Counted
Integration into McKesson’s Medical-Surgical Solutions marketplace serving a nationwide customer base
Phase I results provide platform-level validation supporting AdJane’s broader development programs in pandemic preparedness, respiratory infectious diseases and antimicrobial resistance
International experts from leading universities, global biopharmaceutical companies, and investment organizations will convene in Riyadh, Saudi Arabia, September 14–16, 2026, for the fourth edition of RGMBS.
Leinfelden, Germany. Recent infectious disease events—from hantavirus outbreaks and meningitis cases to recurring disease outbreaks in livestock farming—highlight the need for flexibly scalable vaccine manufacturing processes. To address this challenge, Stuttgart-based technology company KyooBe Tech has developed a platform designed to accelerate vaccine production. This technology is now also available to external users for studies at the Fraunhofer Institute for Cell Therapy and Immunology (IZI).
AmesNet’s Task-Conditioned Learning architecture outperforms FDA, MIT, Tencent, and the University of Sydney models in both sensitivity and balanced accuracy on out-of-domain chemical data on a public dataset; AmesNet is built on top of ChemPrint, the core and proprietary deep-learning engine of the GALILEO platform that powers the company’s drug pipeline.